

Neurotech  
International



# Improving Lives

## Phase I/II Trial Results Webinar

July 2022

**Dr Alexandra Andrews**

PhD Neuroscience, BBMed Sci (Hons1st)  
Chief Executive Officer

**Brian Leedman**

BEd, MBA (UWA)  
Chairman

**Gerald Quigley**

B(Pharm)  
Non-Executive Director



# Disclaimer



## IMPORTANT INFORMATION

**Purpose of presentation:** This presentation (including this document, any related video or oral presentation, any question and answer session and any written or oral material discussed or distributed in relation to this presentation) has been prepared by Neurotech International Limited (ACN 610 205 402) (Neurotech or Company). It has been prepared for the sole purpose of providing general information on Neurotech and its business.

**Not an offer or solicitation:** This presentation is not investment advice nor an offer to subscribe for securities or otherwise invest in Neurotech, and it should not be relied upon to make any investment decision. Further, it does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of securities pursuant to this presentation in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful under applicable law, including the Securities Act of 1933 (USA), as amended (US Securities Act). Securities have not been registered under the US Securities Act or any US state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the US Securities Act and applicable state securities laws.

**Not a prospectus:** This presentation is not a prospectus, product disclosure statement or other investment disclosure document, and the level of disclosure in this presentation is less than such disclosure documents. It has not been lodged with any regulatory or supervisory body. This presentation does not purport to contain all of the information that a prospective investor may require to make an evaluation of Neurotech or its business activities and nothing in this presentation is, or is intended to be, a recommendation to invest in Neurotech. Neurotech does not purport to give financial or investment advice. Account has not been taken of the objectives, financial situation or needs of any recipient of this presentation.

**Forward-looking statements:** This presentation contains forward-looking statements which may be predictive in nature and incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets' or 'expects'. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events.

These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that many of the events are outside Neurotech's control. The stated events may differ materially from results ultimately achieved. Accordingly, neither Neurotech nor any of its directors, employees, contractors or advisors make any warranty or assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur. Further, other than as required by law, Neurotech may not update or revise any forward-looking statement if events subsequently occur or information subsequently becomes available that affects the original forward-looking statement.

**Disclaimer:** Neither Neurotech nor its officers, employees, contractors or advisers make any warranty (express or implied) as to the accuracy, reliability, relevance or completeness of the material contained in this presentation. Nothing contained in this presentation is, or may be relied upon as a promise, representation or warranty, whether as to the past or the future. Neurotech excludes all warranties that can be excluded by law. Except for statutory liability which cannot be excluded, Neurotech, its officers, employees, contractors and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in this presentation and exclude all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

**Professional advice:** Recipients of this presentation should consider seeking appropriate professional financial, taxation and legal advice in reviewing the presentation and all other information with respect to Neurotech and evaluating its business, financial performance and operations.

**Proprietary information and copyright:** This presentation and the information it contains is proprietary to Neurotech. Neurotech holds the copyright in this presentation. Except as permitted under the Copyright Act 1968 (Australia), this paper or any part thereof may not be reproduced without its written permission.

# Webinar Agenda - 8 July 2022


## 15 minute presentation



**Dr Alexandra Andrews**  
CEO




**Brian Leedman**  
Chairman



**Gerald Quigley**  
Non-Executive Director

## 20 minute live Q & A

# Neurotech is a biopharmaceutical company focused on the development & commercialisation of neurological solutions that improve quality of life.



**Successful Phase I/II  
Trial 93% of patients  
showed improvement**



**World's first whole  
plant extract cannabis  
clinical study**



**Exclusive worldwide  
licence**



**PTC Patents lodged**



**Potential for NTI164  
to treat neurological  
disorders**



**Neurotech's Mente  
device & therapy**



# Capital Structure

**\$0.075**

**Share price**  
(as at 1<sup>st</sup> July 2022)

**~\$52M**

**Market  
capitalisation**

**~\$2.33M**

**Cash at bank\***

**697M**

**Share on issue**

**143M<sup>^</sup>**

**Options/rights**



1. \*as at COB 31 March 2022

2. ^Options are comprised at various strike prices between \$0.005 to \$0.09 as at 31 December 2021

# What makes NTI164 different?

## NTI164

VS

## CBD/THC

- ✓ High CBDA
- ✓ Rarer Cannabinoids: CBC, CBDP, CBDB, CBN, CBG
- ✓ Naturally >0.03% THC
- ✓ >4% Terpenes

- ✗ CBDA
- ✗ Rare Cannabinoids
- ✗ Full Plant Extract
- ✗ Patent protected composition





## The Program

### **First in human Phase I/II ASD paediatric study (S8)**

Commenced in May 2021 at Monash Children's Hospital led by A/Prof. Michael Fahey

#### **Open label – single group**

14 patients from 8 to 17yo, Level II and III Autism Spectrum Disorder

#### **Dose regime assessments**

5mg/kg, 10mg/kg, 15mg/kg and 20mg/kg

#### **2,250 Assessment points**

Parameters Anxiety, Participation, Irritability, Hyperactivity, Mood and Self-stimulation

## Outcomes

### 93% of patients showed improvement

#### Global Improvement

64% of patients "much improved"

29% of patients "minimally improved"

7% of patients "no change"

#### Therapeutic Effect (Efficacy Index)

**2 patients Therapeutic Index Score of 2**

Vast Improvement complete or near remission of all symptoms

**10 patients Therapeutic Index Score of 5 & 6**

Decided improvement – Partial remission of symptoms

#### No “washout” period

Due to the positive therapeutic effects of NTI164 combined with feedback from parents and clinicians

**NTI164 measures favourably when compared to other recently completed CBD and/or THC paediatric studies<sup>1,2</sup>**

<sup>1</sup> Thomas, M. & Frampton, C., (2022) HOPE® 1 demonstrates improvements in Clinical Global Impression (CGI) in patients with Autism Spectrum Disorder. [https://zeliratx.com/wp-content/uploads/2022/04/ZEL040-White-Paper\\_Hope\\_FA.pdf](https://zeliratx.com/wp-content/uploads/2022/04/ZEL040-White-Paper_Hope_FA.pdf)

<sup>2</sup> Shani Poleg, et al (2019). Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Progress in Neuro- Psychopharmacology and Biological Psychiatry. <https://www.sciencedirect.com/science/article/abs/pii/S0278584618304445>



# NTI164 Phase I/II Trials

**NTI164 was well-tolerated**

**No serious adverse events recorded**

Across all doses (5, 10, 15 and 20 mg/kg)

**NTI164 shows promise compared to other current treatments**

## **Risperidone**

Existing prescribed medications for the treatment of symptoms associated with ASD have untoward side effects including:

- Weight gain,
- Sedation and
- Hormonal imbalance

***Chief Investigator Professor Fahey,  
Monash Children's Hospital said,***

“I am very encouraged with these results. We have designed a rigorous study on all fronts to assess the potential application of NTI164 for the treatment of ASD. We are encouraged by the efficacy shown by NTI164 in this trial and we are looking forward to the extension of this trial, in addition to the planned initiation of a Phase II/III trial, to further assess the long-term safety and efficacy of NTI164 with the potential to lead to drug registration.”



# Why target Autism Spectrum Disorders (ASD)?

PREVALENCE OF ASD  
~1 in 44 children  
in the US<sup>1</sup>

## Market

ASD is a serious  
neuro inflammatory  
developmental disorder  
that impairs the ability to  
communicate and interact

- Common symptoms include; behavioural issues, agitation, repetitive movements, inability to focus & compulsive neurological patterns



**RISPERIDONE**  
US\$5.6b<sup>2</sup>



**US ANNUAL  
SALES US\$2.1b<sup>3</sup>**  
Ritalin and Concerta  
Active ingredient Methylphenidate

## Current Treatment

Huge unmet medical need -  
patients need better treatment

- Current drugs have numerous side effects; weight gain, breast tissue development, nausea, dry mouth, anxiety, irritability, insomnia, stomach pain & movement disorders

**TREATMENT  
MARKET SIZE  
US\$1.85b<sup>4</sup>**

## Trials

NTI has completed world first  
trial using whole plant (low THC)  
medicinal cannabis strain in  
children with ASD





# Current and Future Opportunities for NTI164

**AUTISM  
SPECTRUM  
DISORDER**

**US\$2.3b<sup>1</sup>**

Phase I/II completed

Phase II/III due to  
commence Q3 2022

**CEREBRAL  
PALSY**

**US\$4.4b<sup>3</sup>**

by 2030

Future Target

**MIGRAINE**

**US\$1.7b<sup>5</sup>**

Future Target

**COMBINATION  
THERAPIES**

Prednisone  
Diclofenac  
& other

**MULTIPLE  
SCLEROSIS**

**US\$20b<sup>2</sup>**

Preclinical studies in  
progress

Future Target

**ADHD**

**\$21b<sup>4</sup>**

Future Target

**TRAUMATIC  
BRAIN  
INJURY**

**US\$2.7b<sup>6</sup>**

Future Target



# Pathways to Commercialisation

The anti-inflammatory properties NTI strains in combination with minimal presence of THC (< 0.3%) provides clear pathways to commercialisation:

## Pharmaceutical

- FDA new drug registration
- Huge potential upside
- Partnering/licensing opportunities

## Combination

- Fast route to commercialisation via the 505B2 route
- Combination with existing drugs i.e. Prednisone, Diclofenac, Celebrex

**GW Pharmaceuticals US\$7.2B  
Acquisition by Jazz Pharmaceuticals<sup>1</sup>**

# Strong Patent Position

Neurotech has lodged two strategic provisional patent applications with IP Australia to underpin future worldwide commercialisation in Neurological applications and has completed international prior art search.

## Composition

Uniqueness of the NTI-164 strain – composition profile with low THC (<0.3%) and a unique combination of ‘rarer’ cannabinoids:  
CBDA, CBC, CBDP, CBDB & CBN


Lodged Oct 2021

## Combination

The application, formulation and use of NTI164

Lodged Oct 2021

# NTI164 Development Program Timeline





# Highly Experienced Executive Team and Board



**Dr Alexandra Andrews**  
CEO

Expertise in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.

Former Director of Operations at NeuroScientific Biopharmaceuticals Ltd.

PhD Neuroscience, BBMed Sci (Hons1st)



**Brian Leedman**  
Chairman

More than 15 years' experience in the biotechnology sector

Co-founder / Director / Chairman of six ASX listed healthcare/ biotechnology companies including: RAP, NGS, NSB, OSL, IMU, ALC

Former Chairman of Ausbiotech (WA)

BEd, MBA (UWA)



**Krista Bates**  
Non-Executive Director

Experienced company director with over 20 years experience in various roles within the Australian capital markets

Core expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance

BA(Hons), GradDip(Law), PostGradDip(Law), GAIDC



**Prof. Allan Cripps AO**  
Non-Executive Director

Distinguished academic, clinical scientist and health services leader

Independent Chair of the Children's Health Research Alliance Board and Non- Executive Director at Bard1 (BD1)

Formerly the Pro Vice Chancellor (Health) at Griffith University and currently professor emeritus at Griffith University

PhD, BSc (Hons), FAHSM, FASM, FAIMS, FIBMS, FCHSM, MACID



**Mark Davies**  
Non-Executive Director

More than 20 years' experience in trading, investment banking & providing corporate advice

Specialises in providing corporate advice & capital raising services to emerging companies seeking business development opportunities and funding from the Australian market

Managing Director of 1861 Capital and co-founder of investment banking firm, Cygnet Capital

BCom




**Winton Willesse**  
Non-Executive Director

Experienced company director with over 20 years experience in various roles within the Australian capital markets

Core expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance

MCom, FFin, CPA, GAICD, FGIA/FCG



**Gerald Quigley**  
Non-Executive Director

Pharmacist and consumer health commentator.


Leading media health commentator heard each week on television and radio stations across Australia.

Extensive knowledge relating to pharmaceutical/nutraceutical product development, dispensing & marketing in addition to product positioning within the relevant regulatory landscapes (eg. TGA, FDA).

B(Pharm)



# Why Invest



**Experienced  
board and  
management**



**Unique  
biopharmaceutical  
cannabinoid  
platform**



**Clinical  
programs  
underway  
targeting pivotal,  
unmet needs**



**Significant  
near term  
milestones  
& newsflow**







# Neurotech

International

## Contact Details

**Dr Alexandra Andrews**  
**CEO**

aa@neurotechinternational.com  
+61 405 339 788

**Media:**

Amalie Schreurs  
White Noise Communications  
amalie@whitenoisecomms.com  
+61 (0)431 636 033

[www.neurotechinternational.com](http://www.neurotechinternational.com)  
[www.mentetech.com](http://www.mentetech.com)

Neurotech International Limited (ASX:  
NTI)